CASE REPORT article
Front. Endocrinol.
Sec. Pediatric Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1654506
Efficacy and Safety of Dose-Escalated Mazdutide, a GLP-1/GCGR Dual Agonist, in an Adolescent with Obesity, Type 2 Diabetes, and Hyperuricemia: A Case Report
Provisionally accepted
- The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Mazdutide, a glucagon-like peptide-1/glucagon receptor (GLP-1/GCGR) dual agonist, has shown marked efficacy in glycemic control, weight loss, and metabolic improvement in adults. However, data in adolescents remain limited. This report explores its therapeutic potential in an adolescent with obesity-related type 2 diabetes mellitus (T2DM) and hyperuricemia (HUA). Study Design and Methods: We report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg/m²), type 2 diabetes mellitus (HbA1c: 9.60%), and hyperuricemia (serum uric acid: 511 μmol/L). The patient underwent a dose-escalation regimen of Mazdutide (2 mg →4 mg →6 mg, administered subcutaneously once weekly) in combination with metformin and insulin to evaluate therapeutic efficacy and safety outcomes. Results: After 36 weeks, the patient showed significant improvement: weight decreased by 16.8 kg (18.89% BMI reduction), uric acid dropped by 37.00%, and HbA1c fell by 21.88%. No hypoglycemic episodes occurred. Lipid levels improved notably: triglycerides fell by 69.02%, total cholesterol by 13.65%, and LDL cholesterol by 17.27%. Hepatic steatosis resolved by week 14, as confirmed by ultrasound. No adverse events were reported, and benefits were sustained post-treatment. Conclusions:Mazdutide exhibited robust metabolic efficacy and good tolerability in an adolescent with obesity, T2DM, and HUA. It improved glycemic control, reduced weight and uric acid, reversed steatosis, and modulated lipid profiles. These findings support its potential as a comprehensive treatment for adolescent metabolic disorders.
Keywords: adolescent obesity, type 2 diabetes mellitus, Hyperuricemia, mazdutide, GLP-1/GCGR Dual Agonist, Adolescent treatment
Received: 26 Jun 2025; Accepted: 20 Aug 2025.
Copyright: © 2025 Cheng, Chen, Li, Zhang, Ma, Liu and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hongwei Jiang, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.